Antony, France, November 10 (ots/PRNewswire) - Following the announcement that Wendel had entered exclusive negotiations with Ares Life Sciences on October 28, 2010, with a view to selling its entire stake (around 46%) in Stallergenes, the company's Works Council met on November 10, 2010. Stallergenes' Works Council having returned a positive consultative ...
Antony, France (ots/PRNewswire) - EUR million 2009 09-Aug 2010 10-Sep EURm %Sales Var.% EURm %Sales Var.% Southern Europe(1) 26 68 9 29.2 70 12 Other EU countries(2) 10.3 27 20 10.6 ...
Antony, France (ots/PRNewswire) - Stallergenes S.A. has announced today the signing of exclusive partnership agreements with Shionogi & Co., Ltd. for two sublingual allergen immunotherapy tablet products resulting from the Stalair(R) program: Actair(R) house dust mite tablets and Japanese cedar pollen tablets. With 32 million respiratory allergy sufferers, there ...
Antony, France, August 27, 2010 (ots/PRNewswire) - - First Half-Year 2010 RESULTS - Excellent 1st Half-Year 2010 Performance by Stallergenes - Growth in France and Internationally +13% - Very Strong net Profit Growth +51% - Free Cash Flow Growth +90% The Board of Directors' approved the 2010 half-year financial statements at its meeting of 25 August 2010, chaired by Albert SAPORTA: ...
Antony, France, June 21, 2010 (ots/PRNewswire) - Stallergenes S.A. announces the results of a phase III clinical trial (VO55.06) conducted in China aimed at assessing the efficacy and safety of sublingual immunotherapy (Staloral(R) mites 300) in adult patients suffering from asthma triggered by house dust mites. Study VO55.06 is a phase III randomized, ...
Antony, France, April 19, 2010 (ots/PRNewswire) - Stallergenes S.A. today announced the first results of a phase III clinical trial (VO61.08) conducted in the USA on its sublingual grass pollen immunotherapy tablet, Oralair(R). This phase III study is the first clinical study in the USA to be conducted by Stallergenes as part of the Oralair(R) ...
Antony, France, April 15, 2010 (ots/PRNewswire) - EURm 2009 09/08 2010 10/09 EURm %Sales Var.% EURm %Sales Var.% Southern Europe 41.8 74 10 46.9 74 12 (1) Other EU countries 12.7 23 36 14.6 23 15 Other markets 1.7 3 0 1.8 3 8 SLIT 47.2 84 16 55.0 87 ...
Antony, France, March 17, 2010 (ots/PRNewswire) - In the news release, "STALLERGENES 2009 : Further Profit Margin Growth and Significant Cash Generation Further Profit Margin Growth and Significant Cash Generation:" issued on 16 Mar 2010 19:50 GMT, by Stallergenes Bloomberg:GENP@FP over PR Newswire, we are advised by a representative of the company that in the section headed '2010 outlook' the second paragraph, ...
Antony, France, March 16, 2010 (ots/PRNewswire) - - Sales up 13%, Operating Profit up 15%, Net Profit up 17% - Record Free Cash Flow of EUR 17.5 Million (x 3.7) - Net Cash Position Turned Positive - Proposed Dividend of 0.55 EUR (up 22%) The Board of Directors' meeting of 15 March 2010, ...
Antony, France (ots/PRNewswire) - Million EUR 2008 08/07 2009 09/08 MEUR %Sales Var.% MEUR %Sales Var.% Southern Europe (1) 36.4 73 14 42.4 74 16 Other EU countries (2) 11.3 23 17 13.1 23 16 Other markets 2.0 4 45 1.5 3 (25) ...
Antony, France (ots/PRNewswire) - Stallergenes has just obtained authorization (IND(1)) from the FDA for immediately launching a phase III clinical trial in the United States with Oralair(R) Grasses in the treatment of allergic rhinoconjunctivitis to grass pollens in adults. The aim of the study, which will ...
Antony, France (ots/PRNewswire) - - 1st Half-Year Sales Up 16% - Revision Upwards of 2008 Sales Growth Guidance: (greater than or equal to)12% ANTONY, France, July 10 /PRNewswire/ -- EUR millions 2006 2007 07/06 2008 08/07 EURM %Sales EURM %Sales % EURM %Sales % ...